StockData
Protara Therapeutics, Inc. logo

Protara Therapeutics, Inc. (TARA) stock

TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/30
$2.32−0.06 (-2.52%)

Close on Nov 17, 2026Market cap $137.10MP/E –Yield –

Protara Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Protara Therapeutics's total assets was $176.09M at Jun 30, 2026. For fiscal 2025 it was $209.47M, up 15.4% from the year before. Over ten years it grew 12.0% a year on average. The highest annual figure on record is $209.47M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$209.47M+15.4%
FY2024Dec 31, 2024$181.45M+129.8%
FY2023Dec 31, 2023$78.95M-30.3%
FY2022Dec 31, 2022$113.29M-34.4%
FY2021Dec 31, 2021$172.60M-15.0%
FY2020Dec 31, 2020$203.16M+16511.4%
FY2019Dec 31, 2019$1.22M-94.8%
FY2018Dec 31, 2018$23.52M-46.5%
FY2017Dec 31, 2017$43.98M+1.1%
FY2016Dec 31, 2016$43.52M-35.6%
FY2015Dec 31, 2015$67.54M-20.4%
FY2014Dec 31, 2014$84.80M+1398.5%
FY2013Dec 31, 2013$5.66M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$176.09M+12.2%
Q1 FY2026Mar 31, 2026$191.92M+13.9%
Q4 FY2025Dec 31, 2025$209.47M+15.4%
Q3 FY2025Sep 30, 2025$144.64M+53.7%
Q2 FY2025Jun 30, 2025$156.93M+54.4%
Q1 FY2025Mar 31, 2025$168.56M+147.4%
Q4 FY2024Dec 31, 2024$181.45M+129.8%
Q3 FY2024Sep 30, 2024$94.09M+6.4%
Q2 FY2024Jun 30, 2024$101.65M+6.8%
Q1 FY2024Mar 31, 2024$68.13M-36.0%
Q4 FY2023Dec 31, 2023$78.95M-30.3%
Q3 FY2023Sep 30, 2023$88.47M-40.5%
Q2 FY2023Jun 30, 2023$95.14M-38.6%
Q1 FY2023Mar 31, 2023$106.41M-34.0%
Q4 FY2022Dec 31, 2022$113.29M-34.4%
Q3 FY2022Sep 30, 2022$148.59M-17.8%
Q2 FY2022Jun 30, 2022$154.88M-18.0%
Q1 FY2022Mar 31, 2022$161.26M-16.2%
Q4 FY2021Dec 31, 2021$172.60M-15.0%
Q3 FY2021Sep 30, 2021$180.70M-9.2%
Q2 FY2021Jun 30, 2021$188.89M+198.6%
Q1 FY2021Mar 31, 2021$192.41M+174.5%
Q4 FY2020Dec 31, 2020$203.16M+16511.4%
Q3 FY2020Sep 30, 2020$198.91M+1961.6%
Q2 FY2020Jun 30, 2020$63.26M+445.3%
Q1 FY2020Mar 31, 2020$70.10M+288.1%
Q4 FY2019Dec 31, 2019$1.22M-94.8%
Q3 FY2019Sep 30, 2019$9.65M-64.8%
Q2 FY2019Jun 30, 2019$11.60M-58.4%
Q1 FY2019Mar 31, 2019$18.06M-53.1%
Q4 FY2018Dec 31, 2018$23.52M-46.5%
Q3 FY2018Sep 30, 2018$27.41M-43.6%
Q2 FY2018Jun 30, 2018$27.85M-17.2%
Q1 FY2018Mar 31, 2018$38.51M+6.9%
Q4 FY2017Dec 31, 2017$43.98M+1.1%
Q3 FY2017Sep 30, 2017$48.56M-1.7%
Q2 FY2017Jun 30, 2017$33.63M–
Q1 FY2017Mar 31, 2017$36.02M–
Q4 FY2016Dec 31, 2016$43.52M–
Q3 FY2016Sep 30, 2016$49.40M–

More Protara Therapeutics figures

See a number that looks wrong?